Progressive Decrease of Left Heschl Gyrus and Planum Temporale Gray Matter Volume in First-Episode Schizophrenia

A Longitudinal Magnetic Resonance Imaging Study

Kiyoto Kasai, MD; Martha E. Shenton, PhD; Dean F. Salisbury, PhD; Yoshio Hirayasu, MD, PhD; Toshiaki Onitsuka, MD, PhD; Magdalena H. Spencer, BS; Deborah A. Yurgelun-Todd, PhD; Ron Kikinis, MD; Ferenc A. Jolesz, MD; Robert W. McCarley, MD

Background: The Heschl gyrus and planum temporale have crucial roles in auditory perception and language processing. Our previous investigation using magnetic resonance imaging (MRI) indicated smaller gray matter volumes bilaterally in the Heschl gyrus and in left planum temporale in patients with first-episode schizophrenia but not in patients with first-episode affective psychosis. We sought to determine whether there are progressive decreases in anatomically defined MRI gray matter volumes of the Heschl gyrus and planum temporale in patients with first-episode schizophrenia and also in patients with first-episode affective psychosis.

Methods: At a private psychiatric hospital, we conducted a prospective high spatial resolution MRI study that included initial scans of 28 patients at their first hospitalization (13 with schizophrenia and 15 with affective psychosis, 13 of whom had a manic psychosis) and 22 healthy control subjects. Follow-up scans occurred, on average, 1.5 years after the initial scan.

Results: Patients with first-episode schizophrenia showed significant decreases in gray matter volume over time in the left Heschl gyrus (6.9%) and left planum temporale (7.2%) compared with patients with first-episode affective psychosis or control subjects.

Conclusions: These findings demonstrate a left-biased progressive volume reduction in the Heschl gyrus and planum temporale gray matter in patients with first-episode schizophrenia in contrast to patients with first-episode affective psychosis and control subjects. Schizophrenia but not affective psychosis seems to be characterized by a postonset progression of neocortical gray matter volume loss in the left superior temporal gyrus and thus may not be developmentally fixed.

Arch Gen Psychiatry. 2003;60:766-775
mismatch stimuli was reduced bilaterally in HG and its vicinity in chronic schizophrenia. Diersk et al demonstrated an increase of functional MRI activation in left hemisphere HG during auditory hallucinations in right-handed patients with schizophrenia.

Kwon et al reported left PT gray matter volume reduction in chronic schizophrenia, and Hirayasu et al reported smaller left PT gray matter volumes in patients with first-episode schizophrenia compared with patients with first-episode affective psychosis and control subjects. However, others did not find such a difference. Evaluations of the PT surface area and length yielded some reports of loss or reversal of normal asymmetry of PT in schizophrenic patients, but others did not find these differences.

The reduced left temporal amplitude of the auditory P300 event-related potential, which has one of its major generators in posterior STG (largely coextensive with PT), has been associated with smaller left posterior STG gray matter volume in both chronic- and, recently, first-episode schizophrenia. Of relevance to progression cortical change, cross-sectional studies on P300 demonstrated an abnormal age-related or duration-of-illness-related latency prolongation in schizophrenia. With respect to clinical correlates of PT, a reduced asymmetry has been associated with more severe thought disorder, and left posterior STG and PT gray matter volume reduction has been associated with the severity of thought disorder. Additionally, a recent functional MRI study has also demonstrated that severity of formal thought disorder was negatively correlated with activation changes in left BA22.

With respect to change over time, several investigators have reported a progressive decrease in MRI gray matter volumes of STG, although findings have been controversial. The retrospective study performed by Mathalon et al demonstrated that male patients with schizophrenia exhibited greater volume decline than control subjects in bilateral posterior STG gray matter. Our laboratory reported smaller gray matter decline in left posterior STG in patients with first-episode schizophrenia compared with patients with first-episode affective psychosis and controls. By contrast, Keeshavan et al reported a reversal of the initial gray matter STG volume reduction with neuroleptic treatment after 1-year follow-up in first-episode schizophrenia. However, to our knowledge, no study to date has evaluated progressive changes in HG and PT gray matter volume.

We report herein a prospective longitudinal study of HG and PT volumes. Our study used MRI scans at baseline (first hospitalization of patients with schizophrenia and affective psychosis) and a subsequent scan approximately 1½ years later, which revealed that schizophrenia, but not affective psychosis, is characterized by progressive gray matter volume reduction in left HG and PT compared with healthy control subjects.

### METHODS

**PARTICIPANTS**

Twenty-two healthy control subjects (2 women) and 28 patients with first-episode psychosis, 13 with schizophrenia (3 women; 11 with paranoid schizophrenia, 1 with disorganized schizophrenia, and 1 with undifferentiated schizophrenia) and 15 with affective psychosis (1 woman; 13 with bipolar disorder and manic disorder and 2 with major depressive disorder), participated in this study (Table 1). Mood-incongruent features were present in 6 of 13 patients with manic psychosis, and all 6 had hallucinations and/or delusions. Mood-congruent features were present in 7 of 13, with 4 of 7 having psychotic features (hallucinations and/or delusions) other than grandiosity. Neither patient group differed significantly in age from the control group, and gender distribution, handedness (all right-handed), and parental socioeconomic status (SES) did not differ among groups. Schizophrenic patients were significantly older than affective psychosis patients and had a significantly lower SES than affective psychosis patients and control subjects.

Patients were recruited from inpatient units at McLean Hospital, Belmont, Mass, a private psychiatric hospital affiliated with Harvard Medical School. Control subjects were recruited through newspaper advertisement. Our earlier study of HG and PT at baseline MRI scan included 66 participants (20, schizophrenia; 24, affective psychosis; 22, control). Thirty-one of these participants (12, schizophrenia; 8, affective psychosis; 11, control) agreed to participation in a second scan and were included in the present study. The remaining 19 participants were newly recruited. The rate of nonparticipation in the second scan (dropout rate) did not differ significantly among groups (chi²=3.24, P=.20). Our local institutional review board approved this study. After a complete description of the study, written informed consent was obtained from all participants.

The protocols for diagnosis and clinical evaluations have been described in detail previously. Briefly, at both baseline and second scan, patients and control subjects met criteria for age (18-55 years), IQ above 75, right-handedness, and a history negative for the following: seizures, head trauma with loss of consciousness, neurologic disorder, and any lifetime history of alcohol or other drug dependence. No control subject had an Axis I or II psychiatric disorder or a first-degree relative with an Axis I psychiatric disorder with screening using the Structured Clinical Interview for DSM-III-R (SCID-NP) by trained interviewers (D.F.S. and M.E.S.), who also diagnosed patients based on the DSM-IV criteria, using the SCID interview and information from medical records. Diagnoses were confirmed at follow-up interview. Consistent with the literature, first episode was operationally defined as the first psychiatric hospitalization.

Median duration of psychotropic medication use before baseline scan was short (Table 1). At the time of the first scan, patients were variously receiving neuroleptics (typical [6, schizophrenia; 9, affective psychosis], atypical [2, schizophrenia; 5, affective psychosis], or both [3, schizophrenia; 0, affective psychosis]); mood stabilizers (lithium carbonate [1, schizophrenia; 5, affective psychosis], valproate sodium [3, schizophrenia; 5, affective psychosis]); or other drugs other than neuroleptics and mood stabilizers (1, schizophrenia; 1, affective psychosis). Typical or atypical neuroleptic status for 1 schizophrenic patient was unknown due to enrollment in a double-blinded olanzapine-haloperidol crossover protocol. Between scans, hospital records and self-reports indicated patients received neuroleptics (typical [1, schizophrenia; 0, affective psychosis], atypical [9, schizophrenia; 5, affective psychosis], or both [0, schizophrenia; 1, affective psychosis]); mood stabilizers exclusively (lithium [3, schizophrenia; 5, affective psychosis], valproate sodium [5, schizophrenia; 7, affective psychosis]); drugs other than neuroleptics or mood stabilizers (1, schizophrenia; 1, affective psychosis); or no drugs or discontinued use of medication (2, schizophrenia; 1, affective psychosis). The medication status for 1 affective psychosis patient was unknown.
Clinical evaluations at baseline and second scan included the Mini-Mental State Examination (MMSE), the information and digits span subscales of the Wechsler Adult Intelligence Scale–Revised (WAIS-R), the Global Assessment Scale (GAS), and each item and 4 syndrome factors of the Brief Psychiatric Rating Scale (BPRS). The schizophrenic patients were significantly older than affective psychosis patients (Tukey honestly significant difference [HSD] tests, \( P = .03 \)).

### MRI ACQUISITION AND PROCESSING

The MRIs were acquired with a 1.5-T scanner (GE Medical Systems, Milwaukee, Wis) and the same acquisition protocol at baseline and second scan. The interscan interval was not significantly different between the 2 psychosis groups. The MRIs were acquired with a 1.5-T scanner (GE Medical Systems, Milwaukee, Wis) and the same acquisition protocol at baseline and second scan. The interscan interval was not significantly different between the 2 psychosis groups.

**Table 1. Demographic and Clinical Characteristics of Study Groups**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Schizophrenic Patients (n = 13)</th>
<th>Affective Psychosis Patients (n = 15)</th>
<th>Control Subjects (n = 22)</th>
<th>( d^* )</th>
<th>( F ) or ( \chi^2 ) Test or ( \chi^2 ) Values</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y†</td>
<td>27.3 (8.5) [18-41]</td>
<td>21.8 (2.9) [18-28]</td>
<td>25.0 (4.3) [18-35]</td>
<td>2.47</td>
<td>3.72</td>
<td>.03</td>
</tr>
<tr>
<td>Male/female</td>
<td>10/3</td>
<td>14/1</td>
<td>20/2</td>
<td>2</td>
<td>2.09</td>
<td>.35</td>
</tr>
<tr>
<td>Handedness‡</td>
<td>0.8 (0.1)</td>
<td>0.7 (0.2)</td>
<td>0.8 (0.2)</td>
<td>2.47</td>
<td>0.48</td>
<td>.62</td>
</tr>
<tr>
<td>SES§</td>
<td>3.7 (1.4)</td>
<td>2.6 (1.3)</td>
<td>2.1 (0.9)</td>
<td>2.47</td>
<td>7.21</td>
<td>.002</td>
</tr>
<tr>
<td>Parental SES</td>
<td>1.9 (0.6)</td>
<td>1.5 (0.7)</td>
<td>1.4 (0.6)</td>
<td>2.47</td>
<td>3.18</td>
<td>.051</td>
</tr>
<tr>
<td>MMSE, baseline scan</td>
<td>27.5 (3.1)</td>
<td>29.1 (1.4)</td>
<td>29.1 (1.2)</td>
<td>2.45</td>
<td>3.14</td>
<td>.053</td>
</tr>
<tr>
<td>WAIS-R, baseline scan</td>
<td>Information, scaled</td>
<td>11.3 (3.7)</td>
<td>12.7 (2.9)</td>
<td>2.43</td>
<td>1.28</td>
<td>.29</td>
</tr>
<tr>
<td></td>
<td>Digits span, scaled</td>
<td>9.8 (2.2)</td>
<td>11.1 (2.8)</td>
<td>2.44</td>
<td>0.83</td>
<td>.44</td>
</tr>
<tr>
<td></td>
<td>Medication dose, baseline scan</td>
<td>196.0 (126.3)</td>
<td>205.6 (145.6)</td>
<td>NA</td>
<td>23</td>
<td>.16</td>
</tr>
<tr>
<td>Age first medicated, y</td>
<td>26.8 (6.6) [18-41]</td>
<td>21.3 (3.1) [17-28]</td>
<td>NA</td>
<td>26</td>
<td>2.32</td>
<td>.02</td>
</tr>
<tr>
<td>Median duration of medication</td>
<td>1 [0-24]</td>
<td>0 [0-60]</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>before baseline</td>
<td>Interscan interval, mo</td>
<td>17.1 (11.0) [9-40]</td>
<td>17.7 (8.1) [9-36]</td>
<td>2.47</td>
<td>0.16</td>
<td>.86</td>
</tr>
<tr>
<td>GAS</td>
<td>Baseline scan</td>
<td>38.5 (10.0)</td>
<td>42.1 (9.2)</td>
<td>NA</td>
<td>26</td>
<td>.97</td>
</tr>
<tr>
<td></td>
<td>Second scan</td>
<td>50.9 (8.3)</td>
<td>63.6 (14.7)</td>
<td>NA</td>
<td>25</td>
<td>2.66</td>
</tr>
<tr>
<td></td>
<td>Total BPRS</td>
<td>Baseline scan</td>
<td>40.8 (12.7)</td>
<td>NA</td>
<td>26</td>
<td>.89</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Second scan</td>
<td>29.4 (5.7)</td>
<td>NA</td>
<td>20</td>
<td>2.59</td>
</tr>
</tbody>
</table>

### REGIONS OF INTEREST

The HG and PT gray matter regions of interest (ROIs) were manually outlined without knowledge of diagnosis or time of scan using a software package for medical image analysis (3D Slicer; software available at http://www.slicer.org) on a workstation (Figure 1). The landmarks for delineating HG and PT gray matter have been previously described in detail, and there were no statistically significant group differences in HG morphologic features.

The initial identification of HG was based on an inspection of the retinocular region in the axial plane. Moving from the superior to inferior slices, we continued to draw convolution(s) of HG. When the anterior boundary of HG was abruptly extended further anteriorly, we stopped drawing on axial slices. This is approximately the point where the transition of HG to anterior STG occurs. Then we added HG on coronal slices, with HG tracing proceeding from the most posterior coronal image with a mark to the most anterior. The first slice of HG in the coronal plane corresponds to the most anterior point of the appearance of the first transverse sulcus. The boundary of HG was finally confirmed in the sagittal plane to ensure that the delineated region was not extended to the anterior STG. In most cases, HG represented a single transverse convolution (left: 85% of schizophrenic patients, 87% of affective psychosis patients, 68% of control subjects; right: 38% of...
schizophrenic patients, 80% of affective psychosis patients, and 73% of control subjects). In the cases of more than one transverse convolution, we followed the literature definition\(^2\,58-60\): when multiple convolutions originated medially from a common stem, all were defined as HG (the sulcus between these convolutions represents the sulcus intermedius of Beck) (left: 15% of schizophrenic patients, 13% of affective psychosis patients, 27% of control subjects; right: 31% of schizophrenic patients, 13% of affective psychosis patients, 23% of control subjects); when they originated separately from the retroinsular regions, only the most anterior gyrus was labeled as HG (left: 0% of schizophrenic patients, 0% of affective psychosis patients, 5% of control subjects; right: 31% of schizophrenic patients, 7% of affective psychosis patients, 5% of control subjects), and more posterior gyri were identified as PT. The prevalence of single HG, multiple transverse gyri from a common stem arising separately was not significantly different among groups (left HG: \( \chi^2 = 2.82, P = .59 \); right HG: \( \chi^2 = 8.25, P = .08 \)).

The posterior border of HG (Heschl sulcus) defined the anterior border of PT. Posteriorly, PT gray matter was traced on coronal images to the end of the sylvian fissure, and the gray matter of the ascending ramus of the sylvian fissure was also included. Thus, our definition of the PT included PT proper and its parietal extension. Once drawn, both HG and PT ROIs could be viewed in any plane and as a 3-dimensional object for any further editing.

For interrater reliability, raters (K.K., T.O., and Y.H.), blinded to group membership, independently drew ROIs. Ten cases were selected at random from the 3 diagnostic groups and from both baseline and second scans, and the raters drew ROIs

Figure 1. A and B, Delineation of the Heschl gyrus and planum temporale on coronal slices, based on magnetic resonance imaging data of a control subject. A, The rostral part of the regions of interest. B, The caudal portion of the planum temporale at the ascending ramus of the sylvian fissure. The gray matter of the Heschl gyrus is labeled dark blue on the subject’s left and green on the subject’s right. The gray matter of the planum temporale is light blue on the subject’s left and yellow on the subject’s right. C, Sagittal view of the Heschl gyrus and planum temporale in the left hemisphere. The coronal lines A and B correspond to the planes of panels A and B, respectively. D, Three-dimensional reconstruction of the Heschl gyrus and planum temporale gray matter superimposed on the axial plane. Each region is labeled using the same color as that in A, B, and C.
on every slice. The intraclass correlation coefficient was 0.95/0.96 for left/right HG gray matter and 0.99/0.99 for left/right PT gray matter. Intra-rater reliability, computed by using all of the slices from 1 randomly selected brain and measured by each of the 3 raters at 2 separate times (approximately 6 months apart), was 0.95 to 0.99 for all structures.

### STATISTICAL ANALYSIS

**HG and PT Volume at Baseline and Second Scan**

We evaluated group differences in ROI (HG or PT) volume separately for baseline and second scan using a repeated-measures analysis of covariance (ANCOVA) with group (schizophrenic, affective psychosis, control) as the within-subjects factor, and age and parental SES as covariates. Relative volume (absolute ROI volume/ICC × 100) was used as the dependent variable for statistical measures, although groups did not significantly differ in ICC volume at baseline or second scan (F2,45 = 1.19, P = .31; F2,45 = 1.53, P = .23, respectively). Of note, the statistical conclusions reported herein remained the same when we used ANCOVA with absolute volume as the dependent variable and ICC as the covariate.

**HG and PT Volume Change Over Time**

We evaluated change over time separately for HG and PT using a repeated-measures analysis of variance with group as the between-subjects factor and hemisphere as within-subjects factors. In the case of interactions with hemisphere, a follow-up repeated-measures analysis of variance (between-subjects factor: group; within-subjects factors: time) was performed for each hemisphere. The statistical significance level was P < .05. Finally, a paired t test was used to compare the volumes of each ROI between baseline and second scans in each group, with a Bonferroni-corrected post hoc t test level of significance set at P < .017 (.05 corrected for the 3 groups). The statistical conclusions reported herein remained the same when adopting ANCOVA with age as the covariate or when an adjustment to the presence or absence of neuroleptic medication between scans in the patient populations (see the “Comment” section for details). Additionally, the statistical conclusions reported herein remained the same after the exclusion of the female participants and also when the manic affective psychosis patients were included.

**Correlational Analysis**

In the case of significantly greater changes in a particular region and hemisphere in one group, exploratory analyses of the correlations between percent change score and the ROI volume (calculated by the formula 100 × (relative volume at second scan – relative volume at baseline scan)/relative volume at baseline scan)) and baseline or absolute change score of clinical measures were performed using the Spearman ρ. In addition, we computed and tested averaged scores across baseline and second scans as a potential compensation for early illness stage fluctuations in symptoms and functioning. Since we considered the analyses to be exploratory in nature, we used P < .05 as the cutoff for reporting statistical significance rather than using a correction for multiple correlations. The values reported herein are those for percent change score of the ROI volume, but all reported correlations were also significant at the P < .05 level for the absolute difference between baseline and second scan ROI relative volumes. In addition, for any ROI in which there was a significant group difference in change score, correlations between change score and interscan interval were also evaluated for each group.

### RESULTS

**HG VOLUME AT BASELINE AND SECOND SCAN**

Age, SES, parental SES, age of first medication, medication dose, duration of medication use before the first scan, and ICC volume at baseline or second scan did not correlate with any of the ROI volumes at baseline or second scan or with the change score of any of the ROI volumes in any group. Although numbers were too small for formal statistical analysis, there was no suggestion that mean change scores of left HG and PT volume differed according to the presence or absence of neuroleptic medication between scans in the patient populations (see the “Comment” section for details). Additionally, the statistical conclusions reported herein remained the same after the exclusion of the female participants and also when only the manic affective psychosis patients were included.

**PT VOLUME AT BASELINE AND SECOND SCAN**

At baseline scan, there was a significant main effect of group (F2,45 = 3.62, P = .04), with no group × hemisphere interaction (F2,45 = 0.12, P = .89). Left HG was larger than right HG for all groups (main effect of hemisphere: F1,45 = 5.91, P = .02). Post hoc tests revealed that total (left plus right) HG volume was significantly smaller in schizophrenic patients compared with affective psychosis patients and control subjects (Tukey honestly significant difference [HSD] tests: P = .008 and P = .007, respectively), but group differences for left and right HG did not reach significance by 1-factor ANCOVA (F2,45 = 1.86, P = .17 [20% reduction relative to controls]; F2,45 = 2.10, P = .14 [16%], respectively).

The statistical results for second scan were similar to those at baseline scan in terms of repeated-measures ANCOVA (main effect of group: F1,45 = 4.92, P = .01; main effect of hemisphere: F1,45 = 4.95, P = .03; group × hemisphere interaction: F1,45 = 0.35, P = .71) and post hoc tests (total HG volume was significantly smaller in schizophrenic patients compared with affective psychosis patients and control subjects [Tukey HSD: P = .003 and P = .002, respectively]). However, 1-factor ANCOVA separately for each hemisphere showed that group differences reached significance for the left hemisphere (F1,45 = 4.47, P = .02 [26% reduction relative to controls]) but not for the right hemisphere (F2,45 = 1.75, P = .19 [19%]).
Table 2. Absolute and Relative Volumes of Regions of Interest at Baseline and Second Scan and Percent Change Over Time

<table>
<thead>
<tr>
<th>Region</th>
<th>Schizophrenic Patients (n = 15)</th>
<th>Affective Psychosis Patients (n = 15)</th>
<th>Control Subjects (n = 22)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Intracranial content, cm³</td>
<td>1498 (107)</td>
<td>1486 (100)</td>
<td>1566 (146)</td>
</tr>
<tr>
<td>Left Heschl gyrus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absolute volume, cm³</td>
<td>1.48 (0.30)</td>
<td>1.89 (0.33)</td>
<td>1.75 (0.28)</td>
</tr>
<tr>
<td>Relative volume, †‡</td>
<td>0.099 (0.020)</td>
<td>0.124 (0.023)</td>
<td>0.124 (0.029)</td>
</tr>
<tr>
<td>Right Heschl gyrus</td>
<td>1.29 (0.35)</td>
<td>1.60 (0.26)</td>
<td>1.90 (0.44)</td>
</tr>
<tr>
<td>Absolute volume</td>
<td>0.086 (0.023)</td>
<td>0.105 (0.017)</td>
<td>0.102 (0.031)</td>
</tr>
<tr>
<td>Left planum temporale</td>
<td>2.05 (0.49)</td>
<td>2.06 (0.39)</td>
<td>2.01 (0.49)</td>
</tr>
<tr>
<td>Absolute volume</td>
<td>0.137 (0.029)</td>
<td>0.135 (0.030)</td>
<td>0.127 (0.028)</td>
</tr>
<tr>
<td>Right planum temporale</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absolute volume</td>
<td>1.90 (0.44)</td>
<td>2.54 (0.54)</td>
<td>2.61 (0.54)</td>
</tr>
<tr>
<td>Relative volume</td>
<td>0.127 (0.027)</td>
<td>0.166 (0.033)</td>
<td>0.167 (0.035)</td>
</tr>
<tr>
<td>Percent change*</td>
<td>−0.9 (1.0)</td>
<td>−1.1 (4.6)</td>
<td>−1.99 (0.49)</td>
</tr>
<tr>
<td>Percent change</td>
<td>−0.7 (1.0)</td>
<td>−0.5 (4.9)</td>
<td>0.127 (0.028)</td>
</tr>
</tbody>
</table>

*Calculated by the following formula: 100 × (volume at second scan−volume at baseline scan)/volume at baseline scan. Negative value indicates decrease in volume.
†Calculated by the following formula: (absolute region of interest volume/intracranial context) × 100.
‡Significantly decreased over time (P<.001).

HG and PT volume changes over time

For HG, group means were significantly different in gray matter volume (main effect of group: F2,47 = 7.21, P = .002), whereas total HG volume did not change over time (main effect of group: F1,47 = 2.33, P = .13). However, a significant group × time × hemisphere interaction (F2,47 = 10.5, P < .001) indicated that at least one group changed over time and that this change differed between the right and left hemispheres. We next compared right and left HGs separately. Subject groups were not significantly different in gray matter volume of right HG (main effect of group: F2,47 = 2.03, P = .14), which also did not change over time (main effect of time: F1,47 = 0.024, P = .88). There was no group × time interaction for right HG (F2,47 = 0.711, P = .50).

In contrast, subject groups were significantly different in gray matter volume of left HG (main effect of group: F2,47 = 6.58, P = .003), and the total gray matter volume for all groups of left HG showed a significant reduction over time (F1,47 = 5.92, P = .02). Moreover, the presence of a highly significant group × time interaction pointed to change in at least one group (F2,47 = 9.62, P < .001). Separate within-group baseline–second scan comparisons revealed that it was the first-episode schizophrenic patients who showed a significant decrease in the gray matter volume of left HG over time (t12 = 4.82, P < .001), whereas neither affective psychosis patients (t12 = −0.73, P = .48) nor control subjects (t12 = −0.377, P = .71) showed changes.

The statistical conclusions for PT were exactly the same as those for HG (main effect of group: F2,47 = 3.49, P = .04; main effect of time: F1,47 = 1.36, P = .25; group × time × hemisphere interaction: F2,47 = 4.66, P = .01). For left PT, there was a significant main effect of group (F2,47 = 9.54, P < .001) and a significant group × time interaction (F2,47 = 15.4, P < .001). The post hoc paired t tests revealed that only schizophrenic patients showed a significant decrease (t12 = 5.11, P < .001), whereas neither affective psychosis patients (t12 = −2.12, P = .052) nor control subjects (t12 = −1.36, P = .19) showed changes. In contrast, for right PT, there was no significant main effect of group (F2,47 = 0.502, P = .61) or time (F1,47 = 0.001, P = .98) and no significant group × time interaction (F2,47 = 0.94, P = .40).

Additionally, the ICC volume did not significantly change from baseline to second scan (main effect of time: F1,47 = 3.57, P = .065), nor was this change different among groups (group × time interaction: F2,47 = 1.57, P = .22). Although the change of ICC over time was small (less than 1% for all groups) (Table 2), we conservatively tested a possibility of whether this trend-level effect of time might have led to a systematic error in ROI volume changes over time. However, ICC change scores (calculated by the following formula: 100 × ((ICC volume at second scan − ICC volume at baseline scan)/ICC volume at baseline scan)) were not correlated with any of the change scores of ROIs (calculated by the following formula: 100 × (absolute volume at second scan − absolute volume at baseline scan)/absolute volume at baseline scan) for any groups. Moreover, the statistical conclusions reported herein did not change when the percent change score of ICC was treated as a covariate.
As an additional measure, a nonparametric Wilcoxon signed rank test confirmed these results; only left HG and left PT in the schizophrenia group showed a non-chance distribution of volume change (for left HG: $z = -3.11, P = .002$, 12 of 13 patients showed decrease; for left PT: $z = -3.18, P = .001$, 13 of 13 showed a decrease) (Figure 2). On average, schizophrenic patients showed 6.9% gray matter volume reduction for left HG and 7.2% for left PT (Table 2). In contrast, for the remaining ROIs, the distribution of volume change was within chance level for all of the groups ($z = -1.76$ to $-0.227$, $P = .078$ to $P = .82$).

CORRELATIONS BETWEEN HG AND PT VOLUMES AND CLINICAL MEASURES

In schizophrenic patients, greater decreases of left HG and left PT volume over time were both significantly correlated with a more severe BPRS baseline score for the “conceptual disorganization” item (HG: $r = -0.641, n = 13$, $P = .02$, PT: $r = -0.581, n = 13$, $P = .04$). There was also a significant HG volume decrease correlation with the mean “conceptual disorganization” score ($r = -0.669, n = 13$, $P = .01$) and the following items: (1) mean score for “suspiciousness” ($r = -0.564, n = 13$, $P = .045$); (2) baseline score for “somatic concern” ($r = -0.559, n = 13$, $P = .047$); and (4) baseline score for “anxiety-depression” factor ($r = -0.573, n = 13$, $P = .04$). Thus, in all cases, the more pronounced the decrease, the worse the BPRS clinical measure. Additionally, left HG and left PT change score did not significantly correlate with the interscan interval in any groups ($r = -0.421$ to $0.227$, $P = .15$ to $P = .60$).

To our knowledge, this is the first prospective study to demonstrate progressive gray matter volume reduction in the 1.5 years following first hospitalization in left HG and left PT in schizophrenic but not in affective psychosis patients. These results indicate the presence of a progressive process in the dominant temporal cortex, subserving auditory perception and language processing, a process that plays a role in the pathophysiology of schizophrenia but not of affective psychosis. We note that the smaller HG and PT gray matter volumes at baseline, although compatible with our prior results, are not a mere replication, since the patient groups only partly overlapped those in our earlier study.10 The principal finding of the present study, however, is the progression of further loss of gray matter volume during the 1.5-year period between scans.

The present prospective study’s gray matter volume reduction during 1.5 years of 6.9% and 7.2%, re-
respectively, for the left HG and PT in first-episode schizophrenia is close to our laboratory’s earlier finding of 9% for the left posterior STG in first-episode schizophrenia but approximately 1.6 times that of the 3% per year for STG in patients with chronic disease found in the retrospective study by Mathalon et al. This suggestion of a more severe volume reduction early in the illness, however, can only be definitively tested through additional scans of the present cohort and additional subjects.

Our group’s previous studies have found differences between first-episode samples of schizophrenic and affective psychoses in posterior STG gray matter and its overlapped subdivisions of HG and PT, as well as in prefrontal cortex, and in fusiform gyrus gray matter. Commonalities of the 2 psychoses at first episode included smaller gray matter volumes of left posterior amygdala-hippocampal complex (mostly hippocampus) and in the subgenual cingulate cortex (trend-level change in schizophrenia). These results suggest that, although smaller gray matter volumes in isocortical regions at first episode may be specific to schizophrenia, some of the abnormalities in limbic and paralimbic regions may be common to both psychoses. Also specific to schizophrenia is the observed progressive change in the isocortical region, and this may be associated with a different functional presentation and outcome between the 2 psychoses. These data also tend to favor the hypothesis that the 2 psychoses may represent manifestations of different disorders, an important but still unresolved question in psychiatry.

In the present study of first-episode schizophrenia, the baseline gray matter volume relative to controls was somewhat smaller in left HG (20% and not statistically significant) than in left PT (24% and statistically significant), findings compatible with the functional data of abnormal P300 but normal mismatch negativity. However, the left HG and PT volume decreases in the subsequent 1.5 years were comparable (6.9% and 7.2%, respectively), which is compatible with the abnormal mismatch negativity seen later in schizophrenia. To obtain an unequivocal and reliable measure, the current study operationally defined first episode as the time of first hospitalization. However, since clinical symptoms of the disorder may have been present for months and even years before the first hospitalization, the present data can neither determine whether abnormalities of structural and functional indices at first hospitalization were consequences of neurodevelopmental deficits and/or perinatal progressive processes nor address the question of whether the progressive volume decreases in left PT began earlier than those in left HG and/or whether left PT might have been more severely affected by a process during neurodevelopment. However, a finding of interest relative to the course of change was that an ANCOVA with interscan interval as the covariate did not affect the significance of the results in the schizophrenia group, compatible with much of the volume decline’s having occurred in the months just after initial hospitalization, rather than being a linear decline over time. A shorter interscan interval will be of help in more accurately fixing the time course of decline.

The precise neurobiological mechanism that underlies this progressive, perhaps neurodegenerative, change in left HG and PT is unknown. However, there is a growing body of work implicating abnormal excitatory amino acid neurotransmission in schizophrenia, possibly mediated through a deficit in recurrent inhibition. Although controversial, this mechanism could be a possible cause of ongoing, use-dependent cellular damage through excitotoxic effects. Our study cannot answer the question of why the left hemisphere is the target for progressive volume reduction. However, left and right HG and PT have some differential cytoarchitectonic features, which may be important in the neurobiological mechanisms for lateralized progressive changes.

In terms of correlations between ROI volume change and clinical measures, the dual finding of association of both left HG and PT ROI volume change with conceptual disorganization in schizophrenia is highly compatible with our early findings of a formal thought disorder–posterior STG association in chronic schizophrenia and with the role of HG and PT in language and auditory processing. The association of HG volume change and suspiciousness may represent the effects of erroneous auditory sensory processing. In chronic schizophrenia, Mathalon et al reported that geometrically defined posterior temporal gray matter volume decline was related to greater BPRS total and negative symptom scores after a mean interscan interval of 4 years. However, we emphasize that our results should be regarded as tentative since the analyses were exploratory in nature and that confirmation in future planned studies will be needed.

In a follow-up MRI study of schizophrenia, the inclusion of medicated patients inevitably raises the question of whether progressive effects are possibly due to medication or the illness itself or whether medication ameliorates the pathologic condition under study. However, medication is almost impossible to control for in human clinical studies. This is also the case with the present naturalistic study, where it was not possible to control prescan or interscan medication type or dosage and where medication compliance was monitored through hospital records and patient accounts but not blood levels. Even so, the available data, because they are unique, may be useful to present. The percent change scores of left HG or PT volume between schizophrenic patients who received neuroleptics between scans (n = 10) and those who did not (n = 3) were not statistically different and visually showed no trends. The affective psychosis patients who received neuroleptics between scans (n = 6) and those who did not (n = 8) did not differ from control subjects in the percent change scores of left HG or left PT volume. Moreover, these 2 subgroups of affective psychosis were not different from each other in percent change scores of left HG or left PT volume. Exclusion of the 8 patients who received lithium also did not alter the statistical conclusions reported herein. The present limited data suggest that medication did not cause the gray matter volume change but are not suitable for drawing conclusions about the possible neuroprotective effects of antipsychotics.

Regarding the dropout rate, of the 66 subjects described in our earlier study at baseline scan, approxi-
mately half (n = 31) underwent a second scan in the present study, and, importantly, the dropout rate did not differ significantly among groups. In addition, the dropout rate was not significantly different among schizophrenic subjects above or below the median value of left HG and left PT volume in the study by Hirayasu et al.10 (Fisher exact test, P > .99). Additionally, the present findings of ROI volumes at baseline are in accord with our earlier study,10 confirming the specificity of smaller bilateral HG and left PT gray matter volume to schizophrenia at first episode, further suggesting the absence of selection bias in subjects undergoing 2 scans. In conclusion, the left HG and PT gray matter volume reduction over time in our sample of subjects with first-episode schizophrenia but not in those with first-episode affective psychosis suggests that a progressive change in the early stage of the illness in brain regions specialized for auditory perception and language processing may play a crucial role in the pathophysiology of schizophrenia.

Submitted for publication March 13, 2002; final revision received September 24, 2002; accepted January 14, 2003.

This study was supported in part by the Department of Veterans Affairs Medical Research Service Merit Awards (Drs Shenton and McCarley) and Middleton Award (Dr McCarley) (Washington, DC); grants K02 MH 01110 and R01 MH 50747 (Dr Shenton), R01 MH 40799 (Dr McCarley), R01 RR 11747 (Dr Kikinis), and P41 PR13218 (Dr Jolesz) from the National Institutes of Health (Bethesda, Md); The MIND Institute (Dr McCarley) (Albuquerque, NM); and the Welfide Medicinal Research Foundation and the Uehara Memorial Foundation (Tokyo, Japan) (Dr Kasai).

We gratefully acknowledge the administrative support of Marie Fairbanks and the research assistant support of Margaret Fagan, AB. We also thank Paul G. Nestor, PhD, and Margaret A. Niznikiewicz, PhD, for their advice on data analysis.

Corresponding authors and reprints: Robert W. McCarley, MD, and Martha E. Shenton, PhD, Department of Psychiatry (116A), VA Boston Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St, Brockton, MA 02301 (e-mail: robert_mccarley@hms.harvard.edu; martha_shenton@hms.harvard.edu).

REFERENCES


